Both preclinical and clinical data showed quicker blood clearance and better blood-brain barrier penetration of radiolabeled HER2-targeted nanobodies in molecular imaging of brain metastatic lesions of HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.